GlassScriptPhysician profile
Nathan R Etten
NPI 1417154774
$9,689.55
in general payments reported to CMS, 2019-2025
29 companies · $1,670 in 2025
The $1,670 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,673 · 2020: $429 · 2021: $1,377 · 2022: $2,102 · 2023: $1,432 · 2024: $1,006 · 2025: $1,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,108.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $2,131.24 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $1,033.92 | 2019-2025 | Acuvue |
| Allergan, INC. | $852.45 | 2019-2021 | |
| Abbvie INC. | $700.08 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $647.47 | 2022-2025 | Infuse |
| Sight Sciences, INC. | $554.24 | 2020-2025 | Tearcare System |
| Biotissue Holdings INC. | $373.40 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $368.09 | 2020-2023 | Cequa |
| Dompe US, INC. | $338.79 | 2021-2025 | Oxervate |
| Visionix USA, INC | $268.08 | 2022 | |
| Lkc Technologies, INC. | $263.78 | 2025 | |
| Genzyme Corporation | $243.59 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $221.80 | 2025 | Xdemvy |
| Alcon Vision LLC | $219.15 | 2022-2025 | Clareon Panoptix Pro |
| Optovue, INC. | $184.35 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $148.08 | 2022-2024 | Tyrvaya |
| Shire North American Group INC | $124.76 | 2019 | |
| Abb Con-Cise Optical Group LLC | $122.41 | 2019 | |
| Horizon Therapeutics Plc | $119.36 | 2021 | |
| Rxsight INC | $118.62 | 2023 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
| Ocular Therapeutix, INC. | $111.33 | 2022-2023 | Dextenza |
| Kala Pharmaceuticals, INC. | $94.47 | 2021 | |
| Amgen INC. | $84.48 | 2024 | Tepezza |
| New World Medical,INC. | $83.74 | 2023 | |
| Visioneering Technologies, INC. | $81.54 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $79.54 | 2019 | |
| Lumibird Medical INC. | $53.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.13 | 2021 | |
| Glaukos Corporation | $27.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Etten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.